Axcella Therapeutics to Participate in the SVB Leerink Global Healthcare Conference

Rhea-AI Summary

Axcella Therapeutics (Nasdaq: AXLA) announced management's participation in the SVB Leerink Global Healthcare Conference, with a fireside chat scheduled for February 17, 2022, at 9:20 a.m. ET. The live webcast will be available on Axcella's website and will remain accessible for 90 days post-event. Axcella is a clinical-stage biotechnology firm focused on treating complex diseases through novel endogenous metabolic modulator (EMM) compositions, targeting conditions such as hepatic encephalopathy, Long COVID, and non-alcoholic steatohepatitis (NASH).

Fireside chat to be webcast at 9:20 a.m. ET on February 17

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced that company management will be participating in the SVB Leerink Global Healthcare Conference.

A live webcast of the company’s fireside chat from this event will be available on the “Investors & News” section of the Axcella’s website, www.axcellatx.com, at 9:20 a.m. ET on February 17, 2022. A replay will be accessible on the website for 90 days following the event.

Internet Posting of Information

Axcella uses its website, www.axcellahealth.com, as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Such disclosures will be included on the company’s website in the “Investors & News” section. Accordingly, investors should monitor this portion of the company’s website, in addition to its press releases, SEC filings and public conference calls and webcasts.

About Axcella Therapeutics (Nasdaq: AXLA)

Axcella is a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using endogenous metabolic modulator (EMM) compositions. The company’s product candidates are comprised of EMMs and derivatives that are engineered in distinct combinations and ratios to restore cellular homeostasis in multiple key biological pathways and improve cellular energetic efficiency. Axcella’s pipeline includes lead therapeutic candidates in Phase 2 development for the reduction in risk of overt hepatic encephalopathy (OHE) recurrence, the treatment of Long COVID, and the treatment of non-alcoholic steatohepatitis (NASH). The company’s unique model allows for the evaluation of its EMM compositions through non-IND clinical studies or IND clinical trials. For more information, please visit www.axcellatx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220209005826/en/

Jason Fredette

jfredette@axcellatx.com

(857) 320-2236

Source: Axcella Therapeutics

FAQ

When is Axcella's fireside chat at the SVB Leerink Global Healthcare Conference?

Axcella's fireside chat is scheduled for February 17, 2022, at 9:20 a.m. ET.

How can I watch Axcella's presentation at the conference?

You can watch Axcella's presentation live on their website, specifically in the 'Investors & News' section.

What is Axcella Therapeutics focused on?

Axcella is focused on treating complex diseases using endogenous metabolic modulator (EMM) compositions.

What diseases are in Axcella's pipeline?

Axcella's pipeline includes candidates for hepatic encephalopathy, Long COVID, and non-alcoholic steatohepatitis (NASH).

How long will the replay of Axcella's fireside chat be available?

The replay will be available on Axcella's website for 90 days following the event.